U.S. Biotech Stock News

On July 21, 2025, Siebert Williams Shank & Co reiterated its ‘Buy’ rating on Crescent Energy Company (NYSE:CRGY) after the company’s Q2 2025 earnings surpassed expectations for operational efficiency and reduced capital expenditures while hitting production targets. An improved tax outlook, large inventory, and continued operational discipline contributed to renewed investor confidence, even as management guided for lower oil production in the coming months. We’ll explore how Crescent...

NYSE:DDS 1 Year Share Price vs Fair Value Explore Dillard's's Fair Values from the Community and select yours...

If you have ever found yourself staring at Apple’s share price and wondering, “Should I buy, sell, or just sit tight?” you are definitely not alone. Apple stock is almost always in the headlines, and lately that has meant plenty of twists and turns that keep even the most seasoned investors on their toes. In the last 90 days, Apple has notched a 12% gain, but the price is still down about 7% year-to-date. That mix of growth and volatility is the kind of cocktail that fuels debate among...

Fidelis Insurance Holdings Limited announced in August 2025 that its second-quarter revenue increased to US$589.3 million from US$540.1 million a year earlier, but net income fell to US$19.7 million compared to US$53.7 million previously, and the company posted a net loss for the first half of 2025. This marks a period where the company achieved higher revenues but experienced a sharp decline in profitability, highlighting a disconnect between top-line growth and bottom-line results. We’ll...

Golar LNG Limited recently announced its second quarter 2025 results, reporting revenue of US$75.67 million and net income of US$15.64 million, while also affirming a US$0.25 per share dividend to be paid in early September 2025. The combination of rising revenue, continued profitability, and the intact quarterly dividend offers insight into Golar LNG’s approach to balancing growth and shareholder returns. To understand how the recently affirmed dividend supports Golar LNG’s investment case,...

Earlier this month, Textron Aviation announced that customers taking delivery of the new Cessna Citation CJ4 Gen3 business jet can now opt for the Gogo Galileo HDX global connectivity solution, expanding inflight internet capabilities with advanced low-earth orbit (LEO) technology and a high-performance HDX antenna. This collaboration extends Gogo’s longtime presence on Cessna aircraft and highlights a growing demand for premium, always-on connectivity in business aviation. We’ll examine how...

On August 19, 2025, Madrigal Pharmaceuticals announced that the European Commission had granted conditional marketing authorization for Rezdiffra as the first and only approved therapy for adults with noncirrhotic MASH with moderate to advanced fibrosis in the European Union. This milestone opens the door to a significant new market, with Madrigal estimating 370,000 patients currently diagnosed and under specialist care for MASH across Europe. We'll examine how this landmark European...

If you have been watching Redwire's stock lately, you are not alone. Investors have good reason to be curious, as the company’s shares have swung dramatically this year, highlighted by strong one-year returns of over 31%, even as the stock came down nearly 50% over the past month. From the outside, this kind of volatility can feel daunting, but it also hints at a story of shifting risk perceptions and potential for big moves ahead, especially as the space technology sector keeps...

ANI Pharmaceuticals recently reported its second quarter 2025 results, showing sales of US$211.37 million and a swing to net income of US$8.55 million, while also raising its full-year earnings guidance to US$818 million–US$843 million. This performance was highlighted by significant growth in the Rare Disease and Generics segments, prompting analysts to update their coverage to reflect the stronger outlook. We'll examine how the raised full-year financial guidance reinforces ANI...

If you have ever wrestled with what to do about Intel stock, you are in good company. Investors are debating whether now is the moment to grab shares of this iconic chipmaker or hold off as industry conditions and tight competition swirl in the background. Over the last three months, Intel has managed a respectable 14.5% gain, shaking off earlier losses and hinting that investors are getting more comfortable with the company’s growth plan. Looking further back, the five-year scorecard is not...

The Progressive Corporation's ( NYSE:PGR ) investors are due to receive a payment of $0.10 per share on 10th of...

On August 13, 2025, ARS Pharmaceuticals reported second quarter and six-month results, with quarterly revenue increasing to US$15.72 million from US$0.5 million a year ago and net loss widening to US$44.88 million from US$12.52 million over the same period. This combination of sharply higher revenue and a significantly larger net loss reflects both increased product uptake and sustained investment needs during commercial expansion. We'll explore how this surge in revenue alongside a growing...

If you are trying to decide what to do with PepsiCo stock right now, you are not alone. Whether you are weighing your next move or just checking in on a long-held position, it is a great time to take stock of what is driving PepsiCo’s share price. Over the last three months, the stock has crept up over 15%, showing a clear bounce from earlier in the year. On a five-year timeline, returns are still strong at 26%, despite a dip in the past twelve months. What is behind these moves? Like many...

Danaher (NYSE:DHR) has been on the radar for many investors lately, thanks to a sharp shift in the company’s share price in the past month. The life sciences and diagnostics giant has climbed 12% since early May, even as the broader market has moved sideways. This movement could catch investors’ attention and prompt questions about what, if anything, has changed for the business beyond the numbers on the screen. Looking at the past year, Danaher’s stock has been under pressure, dropping 22%...

Earlier this month, Open Text Corporation announced a major executive transition, appointing James McGourlay as Interim CEO and introducing organizational changes including a new Executive Committee after recent fourth-quarter earnings results showed revenue of US$1.31 billion and net income of US$28.83 million. Alongside the leadership change, the company raised its quarterly dividend by 5% and unveiled a substantial share repurchase program, reflecting a focus on returning value to...

CorMedix Inc. recently reported its second quarter 2025 results, highlighting a surge in sales to US$39.74 million and a swing to profitability with net income of US$19.83 million, compared to a net loss a year earlier. The company also issued full-year 2025 earnings guidance, projecting pro forma revenue between US$305 million and US$335 million, underlining significant progress following its acquisition of Melinta Therapeutics. We'll examine how CorMedix's shift to profitability and robust...

NasdaqGS:ALXO 1 Year Share Price vs Fair Value Explore ALX Oncology Holdings's Fair Values from the Community and...

If you have been staring at Accenture’s stock price, wondering if now is the right time to make a move, you are definitely not alone. Plenty of investors are reassessing their positions after a bumpy ride over the last year. Let’s be honest: seeing a share that’s been down nearly 22% over the past twelve months can make anyone second-guess their confidence. But if you take a step back, things get more interesting. Despite the recent turbulence, Accenture's five-year return is up over 14%, and...

If you’ve been watching Dow (DOW) lately, you might be scratching your head at its latest swing. The company’s shares have caught some fresh attention, with a sharp drop over the past month that stands out even among cyclical names. There is no big event or dramatic headline in play; rather, a steady move is making investors wonder if the price shift signals something deeper about the company’s prospects or if it is simply the market shifting gears. Across the year, Dow’s share price has...

Are you wondering whether now is the right moment to make a move on Agilent Technologies stock? You are not alone. With all the ups, downs, and headline noise in the market, deciding what to do next can feel trickier than ever. That's where a clear look at valuation—and what it means for you—comes into focus. Agilent’s stock has seen some turbulence lately. Over the past day, shares dipped slightly by about 0.8%, and the past week saw a roughly 1% drop. However, with a broader perspective,...

If you are looking at Abercrombie & Fitch and asking yourself, "Is now the moment to buy, hold, or move on?", you are definitely not alone. Over the past year, the rollercoaster ride of the company's stock price has caught the eye of even the most seasoned investors. In just the last three years, Abercrombie & Fitch’s total return has soared an eye-popping 393%. However, over the past year, the stock has slid by 46%. That kind of volatility makes it tough to know whether this is a growth...

ON Semiconductor (ON) Stock Movement Raises Investor Questions ON Semiconductor (ON) has captured attention after a sharp drop of nearly 18% over the last month, prompting many investors to wonder if the recent price slide is sending a signal about the company's future. There has not been a single headline-grabbing event to trigger the move. In markets, silence can sometimes be just as telling as news. Whether this situation presents an opportunity or a warning sign is a key consideration...

If you have been eyeing DICK'S Sporting Goods and wondering if it deserves a spot in your portfolio, you are definitely not alone. The stock has given investors plenty to talk about lately, with some interesting twists on both the upside and downside. While the share price dipped slightly over the last week, it is up about 3% in the past month and has surged nearly 29% over the past three months. Even more impressive, if you look at a longer snapshot, DICK'S has returned over 120% in the past...

BioCryst Pharmaceuticals recently filed a US$90.2 million shelf registration to offer up to 11,000,000 shares and announced the departure of Dr. Helen Thackray, its chief research and development officer, who will transition to an advisory role through year-end. These developments reflect a simultaneous leadership transition and capital-raising initiative that could influence both operational direction and the company’s financial flexibility. We’ll examine how the shelf registration filing...